MYOVIEW
Peaktetrofosmin
NDAINJECTIONINJECTABLE
Approved
Feb 1996
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
4/8 — Partial
MYOVIEW (tetrofosmin) is (99mtc) tetrofosmin is a lipophilic, cationic complex which diffuses passively through the cell membrane and is locally retained actively due to the presence of intact mitochondria reflecting the presence of viable cells. First approved in 1996.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYOVIEW (tetrofosmin) is a technetium-99m labeled lipophilic cationic complex used for myocardial perfusion imaging to assess coronary artery disease and myocardial viability. The agent passively diffuses across cell membranes and is actively retained in viable mitochondria, allowing visualization of perfusion and cellular integrity. It is administered by intravenous injection for diagnostic nuclear imaging.
Peak3.8 years to LOE
Product is in peak commercial stage with high competitive pressure (8/10); team size and investment level likely stable but facing erosion risk as LOE approaches in ~4 years.
Mechanism of Action
(99mTc) tetrofosmin is a lipophilic, cationic complex which diffuses passively through the cell membrane and is locally retained actively due to the presence of intact mitochondria reflecting the presence of viable cells. After intravenous injection, it is distributed within the myocardium…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches
Started Jul 2006
291 enrolled
Coronary Artery Disease
Why This Matters for Your Career
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.